Evidence map›Paper›PMID 40295666›Full record

ArticleScientific reports2025

A bioinformatics analysis and experimental validation of PDGFD as a promising diagnostic biomarker for acute myeloid leukemia.

Lulu Yang, Shuangshuang Ren, Lijiang Lou, Jiasu He, Qianlei Huang, Xiaojin Wu, Ranran Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lulu Yang *Department of Hematology, Ninghai First Hospital, Ningbo, 315600, Zhejiang, China.
Shuangshuang Ren *Department of Ultrasound, Dongyang People's Hospital, Jinhua, 322100, Zhejiang, China.
Lijiang LouDepartment of Hematology, Ninghai First Hospital, Ningbo, 315600, Zhejiang, China.
Jiasu HeDepartment of Anesthesiology, Ninghai First Hospital, Ningbo, 315600, Zhejiang, China.
Qianlei HuangDepartment of Hematology, The First Affiliated Hospital of Hainan Medical College, Haikou, 570102, Hainan, China.
Xiaojin WuDepartment of Hematology, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China. wuxiaojin@suda.edu.cn.
Ranran ZhaoDepartment of Hematology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, Jiangsu, China. zhaoranran_zrr@163.com.

Funding

The Health and Technology Program of Ningbo 2023Y88the science and Technology Program of Xuzhou ZYSB20210086
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a malignant blood cancer resulting from leukemia stem cells (LSCs) supplanting normal stem cells. Platelet-derived growth factors (PDGFs) are important for LSCs but have not been studied in the development of AML. In this study, transcriptome data of PDGFs were sourced from The Cancer Genome Atlas (TCGA) and GTEx databases, and relevant differential expression and prognosis analysis were performed using R software packages and online tools (UCSC-Xena Shiny tools, GEPIA2, Kaplan-Meier Plotter databases, etc.). Then, we focused on PDGFD expression in AML, along with its clinical and diagnostic importance, drug resistance studies, and association with immunotherapy. The real-time quantitative polymerase chain reaction (RT-qPCR) was performed to verify the expression and clinical characteristics of PDGFD. Analyses of public data and clinical samples revealed that PDGFD expression was upregulated compared with other PDGF genes, and only this upregulation was associated with poor prognosis in AML. High expression of PDGFD showed a significant positive correlation with intermediate-high cytogenetic risk, NPM1 mutation, FLT3-ITD mutation, and unfavorable prognosis. ROC curve analysis indicated that PDGFD holds substantial diagnostic potential for AML patients. Functional enrichment analysis revealed the role of PDGFD in calcium and Rap1 signaling pathways. Additionally, PDGFD expression exhibited a significant positive correlation with natural killer cells and dendritic cells. Furthermore, we propose that MiR-203-3p targeting PDGFD has potential anti-leukemic effects in AML. In conclusion, PDGFD serves as a possible diagnostic and prognostic biomarker, as well as a target for cellular immunotherapy in AML.

Indexed as

Biomarkers, TumorComputational BiologyLeukemia, Myeloid, AcuteLymphokinesPlatelet-Derived Growth FactorFemaleGene Expression ProfilingGene Expression Regulation, LeukemicHumansMaleMiddle AgedMutationNucleophosminPrognosisBiomarkers, TumorLymphokinesNPM1 protein, humanNucleophosminPDGFD protein, humanPlatelet-Derived Growth FactorAcute myeloid leukemiaNatural killer cellNPM1 mutationPDGF familyPrognosis

Identifiers

PMID40295666
PMCPMC12037738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.